TrialX Launches Trialspace at DIA 2016 An Easy to Use Clinical Trials Website Builder with Built-in Recruitment Tracking Tools to Launch Your Study Website in Minutes
Summary
Unlike other clinical trial website creation services, Trialspace entails no upfront cost and comes with month-to-month payment plans.Our past and present: Started in 2008 as a clinical trials decision engine integrated with personal health record platforms such as Google Health and Microsoft HealthVault, TrialX solutions today power clinical trials recruitment and outreach at leading academic medical centers such as University of Pennsylvania School of Medicine, New York University Langone School of Medicine, Beth Israel Deaconess Medical Center and New York Presbyterian Hospital.New York, NY, June 24, 2016 --( PR.com )-- TrialX announces the launch of Trialspace, a clinical trial website builder (http://trialx.com/trialspace) for sponsors, CROs, patient recruitment agencies and investigators.Trialspace comes with a sophisticated patient referral and recruitment tracking engine that is easy to use and provides a 360 degree view of all recruitment activity.Upon signing up, users can specify study details, create pre-screeners, populate study site locations and select from available design themes to launch their entire study site in minutes, not weeks or months.The referral tracking system can be used to create any number of outreach campaigns that track every inbound email, phone call and click.We put patients at the center and build solutions that integrate seamlessly to meet patients where they are.Our past and present:Started in 2008 as a clinical trials decision engine integrated with personal health record platforms such as Google Health and Microsoft HealthVault, TrialX solutions today power clinical trials recruitment and outreach at leading academic medical centers such as University of Pennsylvania School of Medicine, New York University Langone School of Medicine, Beth Israel Deaconess Medical Center and New York Presbyterian Hospital.